The complex balance of PI3K inhibition
Author:
Funder
Pfizer
Roche
Publisher
Elsevier BV
Subject
Oncology,Hematology
Reference18 articles.
1. Genomic characterization of metastatic breast cancers;Bertucci;Nature,2019
2. Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial;Dent;Ann Oncol,2021
3. Everolimus in postmenopausal hormone-receptor–positive advanced breast cancer;Baselga;N Engl J Med,2012
4. Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer;Treilleux;Ann Oncol,2015
5. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial;Di Leo;Lancet Oncol,2018
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. GPD1L may inhibit the development of esophageal squamous cell carcinoma through the PI3K/AKT signaling pathway： bioinformatics analysis and experimental exploration;2024-08-30
2. An update to experimental and clinical aspects of tumor-associated macrophages in cancer development: hopes and pitfalls;Clinical and Experimental Medicine;2024-07-13
3. p4EBP1 staining predicts outcome in ER-positive endocrine-resistant metastatic breast cancer patients treated with everolimus and exemestane;British Journal of Cancer;2024-01-05
4. Beyond Skin Rash: Alpelisib-Induced Anaphylactic Reactions;The Oncologist;2023-04-22
5. Landscape and perspectives of macrophage -targeted cancer therapy in clinical trials;Molecular Therapy - Oncolytics;2022-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3